Overview Wegovy (semaglutide) is a long‑acting GLP‑1 receptor agonist available as a once‑weekly subcutaneous injection and a once‑daily high‑dose oral tablet. It is approved to reduce major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight,…
Diabetes is a global epidemic – in 2022 about 14% of adults had the disease (up from 7% in 1990). It causes serious complications (heart attack, stroke, kidney failure) and over 2 million deaths each year. New therapies are urgently needed.…
This page provides a consolidated and continuously updated overview of FDA novel drug approvals in 2026, covering pharmaceutical products that receive first-time approval in the United States during the calendar year. Unlike the official FDA listing, which presents approvals in…
The FDA establishes rigorous microbiological and chemical standards for high-purity water systems used in pharmaceutical manufacturing. These standards are fundamental to ensuring the safety, efficacy, and sterility of drug products, regardless of whether they are produced domestically or internationally. Water…
The Medicines and Healthcare products Regulatory Agency (MHRA) enforces pharmaceutical manufacturing standards across the United Kingdom through a principles-based, risk-managed regulatory framework aligned with international Good Manufacturing Practice (GMP). This guide provides manufacturers, Quality Assurance professionals, and regulatory affairs teams…
MYQORZO (aficamten) represents a significant advancement in the management of obstructive hypertrophic cardiomyopathy (oHCM), a condition characterized by thickened heart muscle that obstructs blood flow out of the heart. Approved by the FDA in December 2025, it provides a targeted…
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved Lerochol (lerodalcibep-liga), a novel third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor developed by LIB Therapeutics, Inc. Lerochol is approved as an adjunct to diet and exercise to…
HYRNUO® (sevabertinib), a reversible tyrosine kinase inhibitor targeting HER2 (ERBB2), received FDA approval on November 19, 2025, under the accelerated approval pathway for a molecularly defined population of lung cancer patients [Approval Letter, November 19, 2025, Reference ID: 5698585]. This approval…
This post provides a consolidated and structured overview of FDA novel drug approvals in 2025, covering pharmaceutical products that received first-time approval in the United States during the calendar year. Unlike the official listings published by the FDA, this page…
On November 25, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to VOYXACT (sibeprenlimab-szsi), a novel biologic therapy for adults with primary immunoglobulin A nephropathy (IgAN)[3]. Developed by Otsuka Pharmaceutical Company, Ltd., this approval marks a significant…